Urovant’s Gemtesa (vibegron) was the subject of two positive presentations at the Annual Meeting of the American Urological Association (AUA2021). The first explained that vibegron is effective in patients with ‘dry’ overactive bladder (OAB) based on a post-hoc analysis of the pivotal EMPOWUR trial. The second presentation explained that vibegron had a negligible impact on ambulatory…
A closer look at Urovant’s vibegron blood pressure study
In recent years, regulators including FDA have increased their focus on the potential of drugs to cause blood pressure increases. To that end, the agency asked Urovant (Irvine, California) to study the impact of the beta-3 adrenergic receptor agonist vibegron on blood pressure. The study, recently published in the Journal of Urology, found no significant change…
Urovant shares positive data at the annual meeting of the American Urological Association
Urovant Sciences (Irvine, California) is upbeat about the prospects of beta-3 adrenergic receptor agonist Gemtesa (vibegron) in treating overactive bladder (OAB). This week, the drug was featured in two presentations at the virtual American Urological Association (AUA) Annual Meeting. Historically, the primary treatment for OAB involved a type of anticholinergics known as muscarinic receptor antagonists. In…